Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INVITE: Gefitinib vs Vinorelbine in Elderly NSCLC
NCT00256711Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of gefitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-Free Survival. Started Jul 2004; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00256711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00256711.